Ajay Kumar Kakkar

Ajay Kumar Kakkar's AcademicInfluence.com Rankings

Ajay Kumar Kakkar

Chemistry

#4412

World Rank

#5493

Historical Rank

Organic Chemistry

#727

World Rank

#824

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Ajay Kumar Kakkar's Degrees

Bachelors Chemistry Delhi University
Masters Chemistry Delhi University
PhD Pharmaceutical Sciences University of Mumbai

Why Is Ajay Kumar Kakkar Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ajay Kumar Kakkar's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. (2009) (2402)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. (2003) (2222)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (2008) (1426)
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study (2008) (1372)
Venous thromboembolism (VTE) in Europe (2007) (1348)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial (2008) (1115)
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013) (998)
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. (2007) (953)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis (2014) (855)
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. (2013) (799)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. (2020) (757)
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. (2015) (732)
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). (2004) (666)
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. (2011) (528)
Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. (2007) (509)
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. (2005) (475)
Thrombosis: A Major Contributor to Global Disease Burden (2014) (450)
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry (2013) (431)
Predictive and associative models to identify hospitalized medical patients at risk for VTE. (2011) (398)
Platelets and cancer. (2002) (376)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2019) (359)
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study (2007) (350)
Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence) (2006) (344)
Venous thromboembolism prophylaxis and treatment in patients with cancer. (2008) (338)
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. (2011) (335)
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement (2006) (322)
Cancer-associated thrombosis (2010) (322)
Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer (2019) (322)
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2016) (311)
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. (2012) (307)
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty (2010) (273)
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement (2008) (272)
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. (2019) (249)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery (2008) (237)
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation (2016) (220)
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. (2003) (218)
Thrombosis: a major contributor to global disease burden. (2014) (216)
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF (2016) (214)
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). (2012) (196)
Prevention and treatment of venous thromboembolism--International Consensus Statement. (2013) (188)
Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer (2012) (164)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism (2013) (159)
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries (2017) (154)
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer (2015) (154)
Low-molecular-weight heparin and mortality in acutely ill medical patients. (2011) (150)
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. (2007) (142)
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study (2018) (139)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. (2017) (133)
Patients With Cancer (2013) (132)
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. (2009) (125)
Prevention and Treatment of Venous Thromboembolism (2013) (125)
Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry (2016) (122)
Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients (2005) (113)
The role of the coagulation system in tumour angiogenesis. (2001) (111)
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients (2010) (103)
A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II) (2011) (101)
Prevention of venous thromboembolism in cancer patients. (1999) (94)
Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (2015) (87)
Thromboembolism in brain tumors (2001) (80)
Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. (2019) (79)
Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation (2017) (78)
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies (2007) (77)
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation (2018) (77)
Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. (2016) (67)
Thrombosis and cancer (2004) (67)
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™ (2016) (63)
Risk of recurrent venous thromboembolism according to baseline risk factor profiles. (2018) (63)
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. (2020) (63)
Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO (2011) (59)
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry (2018) (58)
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. (2014) (56)
Prevention of fatal pulmonary embolism and mortality in surgical patients (2005) (55)
Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial (2018) (54)
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry (2019) (53)
Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. (2005) (52)
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. (2012) (52)
Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE) (2016) (50)
Current Status of Pulmonary Embolism in General Surgery in Japan (2004) (45)
Can low-molecular-weight heparins improve outcome in patients with cancer? (2002) (44)
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial (2017) (42)
Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey): Findings in Surgical Patients (2010) (41)
Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II (2013) (41)
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding (2008) (39)
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. (2019) (38)
Prevention of venous thromboembolism in the cancer surgical patient. (2009) (37)
Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry (2019) (37)
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. (2011) (37)
Thromboprophylaxis in the Cancer Patient (1998) (34)
Antithrombotic therapy and survival in patients with malignant disease (2010) (34)
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry (2019) (32)
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. (2013) (32)
Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up (2012) (32)
Evolution of genetic abnormalities in hepatocellular carcinomas demonstrated by DNA fingerprinting (1999) (31)
Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery: A Randomized Controlled Trial (2014) (30)
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE (2020) (30)
Low-molecular-weight heparin and survival in patients with malignant disease. (2005) (30)
Evolving quality standards for large-scale registries: the GARFIELD-AF experience (2016) (30)
The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery (2010) (29)
Catheter-associated thrombosis: thromboprophylaxis or not? (2005) (29)
Venous thromboembolism in laparoscopic surgery (2003) (29)
Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. (1997) (29)
Thromboprophylaxis in the Cancer Patient (2001) (28)
Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry (2017) (27)
An expanding role for antithrombotic therapy in cancer patients. (2003) (27)
Improving Practices in US Hospitals to Prevent Venous Thromboembolism: lessons from ENDORSE. (2010) (27)
Enhanced angiogenesis following allogeneic blood transfusion1 (2004) (27)
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry (2018) (27)
Treatment of acute pulmonary embolism with dabigatran versus warfarin (2016) (26)
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism (2016) (25)
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. (2017) (24)
Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry (2019) (23)
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial. (2007) (23)
Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement. (2002) (23)
Antithrombotic therapy in cancer (1999) (22)
Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI) (2018) (22)
Low- and ultra-low-molecular-weight heparins. (2004) (22)
Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. (2019) (21)
American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. (2007) (20)
Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial. (2007) (20)
Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial (2017) (19)
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation (2020) (18)
Management of venous thromboembolism. (2007) (18)
Inferior Vena Cava Filters (2013) (17)
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. (2021) (17)
8 Venous thromboembolism and cancer (1998) (17)
The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events (2019) (16)
GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study (2019) (16)
Gynecology and Obstetrics (2013) (15)
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. (2020) (15)
Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: Implications for atrial fibrillation screening. (2021) (15)
Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF (2021) (14)
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial (2022) (14)
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. (2017) (14)
Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries. (2020) (14)
GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. (2020) (14)
Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease (2020) (14)
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use. (2008) (14)
New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF. (2019) (13)
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II (2017) (13)
Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study (2006) (13)
Binding and inhibition of drug transport proteins by heparin (2014) (13)
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists (2016) (13)
New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF (2019) (13)
Prevention of perioperative venous thromboembolism: outcome after cancer and noncancer surgery (2001) (12)
Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial (2020) (12)
Retroperitoneal myolipoma (2005) (12)
Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™ (2014) (12)
Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF. (2018) (11)
Abstract 18594: Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVER™ II (2014) (10)
Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry (2019) (10)
Treatment for Patients With Cancer (2013) (10)
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) (2019) (10)
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE (2021) (10)
Contaminated heparin. (2008) (10)
Incidence of Venous Thromboembolism in Orthopedic Surgery (2013) (10)
Comparative effectiveness of oral anticoagulants in everyday practice (2021) (10)
Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights (2013) (10)
Incidence of Venous Thromboembolism in Orthopedic Surgery (2013) (10)
Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) (2018) (9)
Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN Study (2013) (9)
Implementing Thrombosis Guidelines in Cancer Patients: A Review (2014) (9)
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE) (2003) (9)
Venous thromboembolism and cancer. (2007) (9)
Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism. (2009) (9)
Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey (2008) (8)
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications. (2008) (8)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry (2018) (8)
Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing. (2006) (8)
Outcomes in newly diagnosed atrial fibrillation and history of acute coronary syndromes: insights from GARFIELD-AF. (2019) (8)
Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor. (2005) (8)
Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. (2021) (8)
Treatment of deep vein thrombosis in cancer: A comparison of unfractionated and low molecular weight heparin. (2000) (8)
Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE (2021) (8)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry (2018) (8)
Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation (2008) (7)
Venous thromboembolism prophylaxis for the general surgical patient: where do we stand? (2008) (7)
A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. (2003) (7)
Diagnosis and Anticoagulant Treatment * (2013) (7)
The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients. (2004) (7)
Giant spinal arachnoid cysts: computed tomography, magnetic resonance imaging and magnetic resonance myelography correlation. (2000) (7)
Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2-VASc score ≥ 2? (2019) (6)
Is the natural history of venous thromboembolism different in surgical and non-surgical-patients? Findings from the RIETE registry. (2003) (6)
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. (2021) (6)
Medical patients. (2013) (6)
INAPPROPRIATE UTILIZATION OF ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION: THE GLOBAL ANTICOAGULANT REGISTRY IN THE FIELD (GARFIELD) REGISTRY (2012) (6)
What is the role for antithrombotics in cancer care? Interactive session with panel discussion. (2002) (6)
A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study (2017) (6)
Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry (2021) (6)
P4602Similar clinical outcomes of asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF (2017) (6)
POOLED ANALYSIS OF FOUR STUDIES OF RIVAROXABAN: EFFECT ON SYMPTOMATIC EVENTS AND BLEEDING AND THE INFLUENCE OF CLINICALLY RELEVANT PATIENT SUBGROUPS (2009) (6)
Low-molecular-weight heparins: beyond thrombosis in the management of the cancer patient. (2003) (6)
Antithrombotic therapy with low molecular weight heparin in cancer patients. (2004) (6)
[Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): results obtained in France]. (2011) (6)
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey (2020) (5)
CD11b+ leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes (2011) (5)
Thrombosis and cancer. (2006) (5)
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation (2021) (5)
Introduction - Uncharted territories in thrombosis care: Expanding into new areas (2002) (5)
Sunday, 26 August 2012 (2012) (5)
Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial (2018) (5)
Partnership Model for Academic Health Science Systems to Address the Continuum from Discovery to Care, at Scale (2013) (4)
P3569Impact of body mass index in newly diagnosed atrial fibrillation in the GARFIELD-AF registry (2017) (4)
Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban. (2009) (4)
Treatment of venous thromboembolism in cancer patients. (2007) (4)
Abstract 12422: Influence of Polypharmacy on the Efficacy And Safety Of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER® and RE-COVER II™ (2015) (4)
3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups (2011) (3)
Current use of venous thromboembolism prophylaxis in cancer patients. (2009) (3)
Cost-Effectiveness of Prevention and Treatment of VTE (2013) (3)
O-163 Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2) (2005) (3)
Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial (2018) (3)
Tissue Factor, Thrombin Generation and Cancer (1996) (3)
Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor: Pooled results of two phase Iib clinical trials. (2005) (3)
Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial (2017) (2)
Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry (2022) (2)
Antithrombotics and Cancer: Evidence for Survival Benefit (2003) (2)
Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data (2021) (2)
Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]. (2020) (2)
One-year outcomes in atrial fibrillation patients with versus without a previous stroke or transient ischaemic attack: findings from the international prospective GARFIELD registry (2013) (2)
Direct current conversion and clinical events at 1 year in patients with non-valvular atrial fibrillation. The Global Anticoagulant Registry in the FIELD (GARFIELD) (2013) (2)
1354The effect of non-recommended dosing of non-vitamin K antagonist oral anticoagulants (NOACs) on 1-year mortality in patients with newly diagnosed AF? Results from the GARFIELD-AF registry (2018) (2)
TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY (2017) (2)
Combined Modalities in Surgical Patients (2013) (2)
Abstract 18357: Outcomes and Quality of Anticoagulant Control in Patients Newly Diagnosed with Non-valvular Atrial Fibrillation: Insights from the Worldwide GARFIELD Registry (2012) (2)
Surgical thrombectomy. (2013) (2)
General, Vascular, Bariatric, and Plastic Surgical Patients (2013) (2)
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. (2011) (2)
Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism (2014) (2)
Venous thromboembolism pharmacologic prophylaxis after major surgery--are we doing well or not well enough? (2011) (2)
Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD registry (2013) (2)
Anti-thrombotic Therapy in Cancer Patients (2009) (2)
33Patterns of antithrombotic therapy in relation to type of atrial fibrillation: insights from the UK cohort of the global GARFIELD registry (2014) (2)
Thrombosis Research Institute (1990) (2)
The Importance of the Design of Observational Studies in Comparative Effectiveness Research: Lessons from the GARFIELD-AF and ORBIT-AF registries. (2021) (1)
Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation: UK findings from the GARFIELD-AF registry (2016) (1)
Key Questions to be Answered (2013) (1)
THE EFFECT OF PATIENT AGE, GENDER AND WEIGHT ON THE EFFICACY AND SAFETY OF RIVAROXABAN (BAY 59-7939) FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY (2009) (1)
The effect of body mass index on clinical outcomes in patients with newly diagnosed atrial fibrillation in the GARFIELD-AF registry (2020) (1)
Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study (2021) (1)
Thrombolytic Therapy (2013) (1)
Tuesday, 28 August 2012 (2012) (1)
TIMING OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AND BLEEDING EVENTS AFTER TOTAL KNEE ARTHROPLASTY: A POOLED ANALYSIS OF RIVAROXABAN STUDIES (2011) (1)
Critical Care Medical Patients (2013) (1)
Venous thromboembolism and cancer. (2007) (1)
Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey. (2008) (1)
An overview of thromboprophylaxis in malignancy. (2001) (1)
P2889The economic burden attributable to atrial fibrillation in nine European countries: perspectives from the GARFIELD-AF registry (2018) (1)
Orthopedic Surgery and Trauma (2013) (1)
Thrombosis, Anti-thrombotic Therapy and Cancer (1998) (1)
The Problem and the Need for Prevention (2013) (1)
Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies. (2005) (1)
Impact of NOAC and VKA on outcome of patients with newly diagnosed atrial fibrillation and diabetes: a report from the GARFIELD-AF registry (2021) (1)
Stroke and bleed related deaths in newly diagnosed atrial fibrillation patients: insights from the GARFIELD-AF registry (2022) (0)
Twelve-month outcomes in paroxysmal versus permanent atrial fibrillation: data from the prospective, international GARFIELD registry (2013) (0)
Tissue factor, thrombin generation and cancer. (2002) (0)
3B.3 Prevention and treatment of cancer associated thrombosis (2007) (0)
360Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry (2018) (0)
Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF (2022) (0)
Comparative effectiveness of NOAC vs VKA in patients representing common clinical challenges: results from the GARFIELD-AF registry (2021) (0)
Prevention of Postthrombotic Syndrome (2013) (0)
Introduction: building on a heritage in thrombosis – perspectives in cancer care (2002) (0)
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide (2022) (0)
ORAL, ONCE-DAILY RIVAROXABAN FOR THE PREVENTION OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY: A META-ANALYSIS OF THREE PIVOTAL STUDIES (2008) (0)
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide (2022) (0)
Two-year outcomes of patients with atrial fibrillation treated with rivaroxaban: results from RIVER registry (2021) (0)
Abstract 20326: Impact of Gender on Clinical Outcomes in Non-Valvular Atrial Fibrillation: Contemporary Perspective From the GARFIELD Registry (2014) (0)
Systemic or Venous Thromboembolism Global Anticoagulant Registry in the Field – Venous Thromboembolism ( GARFIELD-VTE ) Rationale and design (2016) (0)
Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry (2023) (0)
Other Uses of LMWHs – Miscellaneous (1998) (0)
Daily challenges in oncology practice (2006) (0)
Evaluation of the risk and prophylaxis of venous thrombo-embolic events in medical hospitalised patients: results in France of the international survey endorse (2009) (0)
Does Obesity Influence Physician Practices in Provision of Prophylaxis for Venous Thromboembolism? Lessons from IMPROVE (2004) (0)
PREVENTION OF VENOUS THROMBOEMBOLISM WITH RIVAROXABAN AFTER TOTAL HIP REPLACEMENT: ECONOMIC IMPACT OF EXTENDED THROMBOPROPHYLAXIS (2010) (0)
Urologic Surgery (2013) (0)
One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD registry (2013) (0)
Safety and efficacy of apixaban and rivaroxaban versus warfarin in real-world atrial fibrillation patients are similar to their randomized trials: insights from GARFIELD-AF registry (2021) (0)
P4603The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry (2017) (0)
THE PRESCRIBING OF ANTIPLATELET THERAPY ONLY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY (2017) (0)
Preventing venous thromboembolism (VTE) in hospitalised patients: putting guidance into practice (2008) (0)
Belgian Society of Cardiology Belgian Heart Rhythm Association (BeHRA) (2011) (0)
Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
Venous thromboembolism: a UK perspective. (2009) (0)
Abstract 19998: Event Rate in Patients with Atrial Fibrillation who Discontinue Oral Anticoagulant Therapy Early: Results from the GARFIELD Registry (2014) (0)
Abstract 18738: Use of Antithrombotic Therapies and Outcomes in Patients with Atrial Fibrillation and Heart Failure: Insights from the GARFIELD Registry (2014) (0)
Rhythm versus rate control in patients with newly diagnosed atrial fibrillation: observations from the GARFIELD-AF registry (2022) (0)
RIVAROXABAN (BAY 59-7939) – A NOVEL, ORAL, DIRECT FACTOR XA INHIBITOR – FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY: OVERVIEW OF THREE PHASE II TRIALS (2009) (0)
EARLY MORTALITY IN PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY (2017) (0)
Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
Metastatic Breast Cancer or Stage III / IV Lung Cancer Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in (2012) (0)
Venous thromboembolic risk and suboptimal prophylaxis in the US acute hospital care setting: Findings from the ENDORSE study (2007) (0)
A Multinational Comparison of Prophylaxis Practices for Venous Thromboembolism During Medical Intensive Care: Findings from IMPROVE (2004) (0)
Antithrombotic Therapy and Cancer (2002) (0)
THROMBOPROPHYLAXIS AFTER ORTHOPAEDIC SURGERY WITH BAY 59-7939–AN ORAL, DIRECT FACTOR XA INHIBITOR: (2008) (0)
Wednesday, 29 August 2012 (2012) (0)
Chapter 2 Incidence of Venous Thromboembolism in Orthopedic Surgery (2017) (0)
Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF (2020) (0)
International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients (2012) (0)
Antimalignant properties of antithrombotic agents (2004) (0)
ATRIAL FIBRILLATION TREATMENT PARADOX: CHARACTERISTICS OF AND FIRST-YEAR EVENTS IN PATIENTS NOT TREATED WITH VITAMIN-K ANTAGONISTS COMPARED TO TREATED PATIENTS. THE GARFIELD REGISTRY (2013) (0)
PAPER 147: RECORD2: A PHASE III EVALUATION OF THE EFFICACY AND SAFETY OF EXTENDED THROMBOPROPHYLAXIS WITH RIVAROXABAN COMPARED WITH SHORT-TERM ENOXAPARIN FOLLOWING TOTAL HIP REPLACEMENT (2010) (0)
Is cardiovascular death a primary driver of mortality in higher age groups of patients with non-valvular atrial fibrillation? Results from the GARFIELD-AF Registry (2014) (0)
Permanent discontinuation of different anticoagulants in patients with atrial fibrillation and the impact on clinical outcome: data from the GARFIELD-AF registry (2020) (0)
Outcomes at 1 year in atrial fibrillation patients with versus without an acute coronary syndrome: insights from the prospective GARFIELD Registry (2013) (0)
Incidence and risk factors (2004) (0)
Clinical outcomes of patients with newly diagnosed atrial fibrillation who refused anticoagulation: findings from the global GARFIELD-AF registry (2020) (0)
PAPER 146: A COMPARISON OF THE EFFICACY AND SAFETY OF ORAL RIVAROXABAN AND SUBCUTANEOUS ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS FOLLOWING TOTAL HIP REPLACEMENT: RECORD1 (2010) (0)
Questionnaire for Trial Submission (2000) (0)
Venous Thromboembolism and Its Treatment in High-Risk Groups (2003) (0)
One-year outcomes in atrial fibrillation patients with versus without coronary artery disease. The prospective Global Anticoagulant registry in the FIELD (GARFIELD) (2013) (0)
Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™ (2015) (0)
P4790Haematuria is not elevated in AF patients treated with NOACs versus VKAs: GARFIELD-AF study (2019) (0)
P4800Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score? (2018) (0)
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease (2022) (0)
Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score? (2019) (0)
Prevention of venous Thromboembolism in the Surgical Patient with Cancer (2009) (0)
Abstract related to PL-22 Guidelines for antithrombotics in cancer patients (2012) (0)
Blood transfusion is associated with an enhanced pro angiogenic state (2003) (0)
P2895Evaluation of the effect of oral anticoagulants on all-cause mortality within 3 months of the diagnosis of atrial fibrillation: results from the GARFIELD-AF prospective registry (2018) (0)
Differential efficacy and safety of oral anticoagulation in atrial fibrillation patients with or without comorbid vascular disease: insights from the GARFIELD-AF registry (2022) (0)
Comparing rivaroxaban and apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria (2021) (0)
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. (2022) (0)
Thromboprophylaxis [3] (multiple letters) (2002) (0)
Immobility and advanced age: Critical factors contributing to the overall risk of venous thromboembolism in medical patients. (2003) (0)
P4601Differences in two-year outcomes according to type of atrial fibrillation: results from the GARFIELD-AF registry (2017) (0)
Global healthcare resource use in 39,670 patients with AF: perspectives from GARFIELD-AF (2017) (0)
The Thrombosis Research Institute, London. (2019) (0)
Rivaroxaban dosing in patients with atrial fibrillation: results from the RIVER registry – is dosing according to renal function appropriate? (2021) (0)
P3848Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher? (2018) (0)
Abstract (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ajay Kumar Kakkar?

Ajay Kumar Kakkar is affiliated with the following schools: